NCT02630186View on ClinicalTrials.gov

A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

February 24, 2016

Primary Completion Date

September 5, 2017

Study Completion Date

September 5, 2017

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Rociletinib

A novel, potent, covalent (irreversible) small molecule, tyrosine kinase inhibitor (TKI) administered orally (PO) to patients with EGFRm NSCLC.

DRUG

MPDL3280A

A human IgG1 monoclonal antibody administered intravenously (IV)

Trial Locations (1)

90404

University of California at Los Angeles, Santa Monica

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Clovis Oncology, Inc.

INDUSTRY